GE HealthCare’s order book and new product launches look promising, but long delays from approval to installed equipment mean much of the payoff may arrive later than many expect. Meanwhile, newer imaging drugs and software upgrades could add growth—or run into pricing pressure, supply bottlenecks, and extra costs along the way.Read more
GE HealthCare is pushing into new hospital partnerships and rolling out next‑gen imaging and diagnostic tools that could open up new demand and make sales less dependent on one‑off equipment buys. But trade tensions, shifting rules in China, and fast‑moving rivals could squeeze profits and slow momentum.Read more
GE HealthCare is betting that a new wave of clearer CT scans, upgraded MRI systems, and smarter software can turn its imaging business into a steadier, higher-earning engine over time. The big question is whether product rollouts and approvals arrive on schedule and hospitals adopt them fast enough, while costs, tariffs, and China-related pressure stay manageable.Read more
No trending discussion available.
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women’s health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women’s health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
